샘플 요청 목록

 카트 문의
시장보고서
상품코드
1452675

세계의 악성중피종 시장 : 업계 분석, 규모, 점유율, 성장, 동향, 예측(2031년) - 약제 유형별, 투여 경로별, 유통 채널별, 지역별

Malignant Mesothelioma Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
발행일: | 리서치사: Fairfield Market Research | 페이지 정보: 영문 223 Pages | 배송안내 : 2-5일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 악성중피종 시장 규모는 패러다임 이동을 맞이하고 있으며, 페메트렉세드와 병용 요법 분야가 치료 접근법에 혁명을 일으키는 프론트 러너로서 대두하고 있습니다. 이 부문은 예측 기간이 끝날 때까지 45% 이상의 수익 점유율을 차지하며 시장의 대부분을 차지할 것으로 예측됩니다. 연평균 성장률(CAGR)은 7.4%로 눈부시게, 뛰어난 연주효율과 병용요법에 대한 주목이 높아짐에 따라, 이 분야는 3억 달러를 넘을 기세입니다.

페메트렉세드는 단독 요법이나 타제와의 병용 요법에서도 현저한 효능을 나타내기 때문에 악성중피종 치료의 요지로서의 지위가 확립되고 있습니다. 임상시험 결과, 페메트렉세드를 병용한 경우의 연주효율은 30%-40%인 것이 밝혀져 시장 점유율의 대폭적인 확대로의 길이 열렸습니다. 각 회사는 다른 약물의 시너지 효과를 이용하여 환자의 결과를 향상시키는 새로운 병용 요법의 승인을 얻기 위한 노력을 강화하고 있습니다.

악성중피종 치료에서 병용 요법의 잠재력을 탐구하기 위해 업계 각 회사 간의 공동 연구가 중요한 전략으로 부상하고 있습니다. 절차에 대한 특허를 보유한 기업의 수가 제한되어 있기 때문에 다양한 약물 조합에 초점을 맞춘 공동 연구 이니셔티브가 지지를 받고 있습니다. 특히 베링거 잉겔하임에 의한 닌테다닙과 페메트렉세드/시스플라틴의 병용 요법의 3상 시험은 치료 옵션을 늘리고 치료 전망을 넓히기 위한 협조적인 노력을 보여줍니다.

본 보고서에서는 세계의 악성중피종 시장에 대해 조사했으며, 시장 개요와 함께 약제 유형별, 투여 경로별, 유통 채널별, 지역별 동향 및 시장 진출기업의 경쟁 동향 등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

  • 시장 정의 및 세분화
  • 시장 역학
  • 밸류체인 분석
  • Porter's Five Forces 분석
  • COVID-19의 영향 분석
  • 우크라이나와 러시아의 분쟁의 영향
  • 경제 개요
  • PESTLE 분석

제3장 세계의 악성중피종 시장 전망(2018-2031년)

  • 세계의 악성중피종 시장 전망 : 약제 유형별, 금액(10억 달러)(2018-2031년)
  • 세계의 악성중피종 시장 전망 : 투여 경로별, 금액(10억 달러)(2018-2031년)
  • 세계의 악성중피종 시장 전망 : 유통 채널별, 금액(10억 달러)(2018-2031년)
  • 세계의 악성중피종 시장 전망 : 지역별, 금액(10억 달러)(2018-2031년)

제4장 북미의 악성중피종 시장 전망(2018-2031년)

제5장 유럽의 악성중피종 시장 전망(2018-2031년)

제6장 아시아태평양의 악성중피종 시장 전망(2018-2031년)

제7장 라틴아메리카의 악성중피종 시장 전망(2018-2031년)

제8장 중동 및 아프리카의 악성중피종 시장 전망(2018-2031년)

제9장 경쟁 구도

  • 약제 유형별 및 투여 경로별 히트맵
  • 기업의 시장 점유율 분석(2023년)
  • 경쟁력 대시보드
  • 기업 프로파일
    • AstraZeneca Plc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Eli Lilly and Company
    • Teva Pharmaceuticals
    • Boehringer Ingelheim GmbH
    • Mylan NV
    • Fresenius Kabi AG
    • Sun Pharmaceuticals Industries Ltd
    • Corden Pharma International GmbH
    • Concordia International Corp

제10장 부록

AJY 24.04.09

The global malignant mesothelioma market is witnessing a paradigm shift, with the Pemetrexed and combination therapy segment emerging as the frontrunner in revolutionizing treatment approaches. According to comprehensive market analysis, this segment is anticipated to capture a significant portion of the market, accounting for over 45% revenue share by the end of the forecast period. With an impressive compound annual growth rate (CAGR) of 7.4%, the segment is poised to exceed US$ 300 million, driven by its superior response rates and increasing focus on combination therapies.

Enhanced Efficacy Fuels Growth

The remarkable efficacy demonstrated by Pemetrexed, either as a standalone therapy or in combination with other drugs, underscores its position as the cornerstone of malignant mesothelioma treatment. Clinical studies have revealed response rates ranging from 30% to 40% when Pemetrexed is used in combination, paving the way for a significant expansion in market share. Companies are intensifying efforts to secure approvals for novel combination therapy regimens, leveraging the synergistic effects of different drugs to enhance patient outcomes.

Collaborative Research Drives Innovation

Collaboration has emerged as a key strategy among industry players to explore the potential of combination therapies in malignant mesothelioma treatment. With a limited number of companies holding patents for procedures, collaborative research initiatives have gained traction, focusing on diverse combinations of drugs. Notably, Boehringer Ingelheim's phase 3 study of Nintedanib in combination with Pemetrexed/Cisplatin exemplifies the concerted efforts towards advancing treatment options and expanding the therapeutic landscape.

Rising Incidence Promotes Market Growth

Contrary to assumptions based on asbestos restrictions, the incidence of malignant mesothelioma continues to rise, particularly among men. Statistics released by Cancer Research UK highlight a concerning trend, with 1 in every 140 men and 1 in every 710 women diagnosed with the disease. This demographic shift underscores the urgent need for effective therapeutic interventions, propelling the demand for Pemetrexed and combination therapies.

Exploring Combination Therapies

The evolution of combination therapies represents a pivotal advancement in the management of malignant mesothelioma, offering a multifaceted approach to tumor regulation. By targeting multiple pathways involved in tumor progression, combination therapies hold promise in significantly improving survival rates. Various modalities, including chemotherapy combined with radiotherapy, targeted antibodies, cryotherapy, and immunotherapies, are poised to expand the potential indications for existing drugs, providing hope for patients and clinicians alike.

Regional Dynamics

While the global market for malignant mesothelioma is poised for substantial growth, regional variations in market dynamics are evident. The Asia Pacific, Latin America, and Middle East & Africa regions are projected to witness the highest CAGRs for the Pemetrexed and combination therapy segment. With a market attractiveness index of 2.7, Latin America emerges as a particularly promising market, reflecting the growing acceptance and adoption of innovative treatment modalities.

Key Companies

  • AstraZeneca Plc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
  • Eli Lilly and Company
  • Teva Pharmaceuticals
  • Boehringer Ingelheim GmbH
  • Mylan N.V.
  • Fresenius Kabi AG
  • Sun Pharmaceuticals Industries Ltd
  • Corden Pharma International GmbH
  • Concordia International Corp
  • Kyowa Hakko Kirin Co Ltd.
  • Polaris Pharmaceuticals, Inc.
  • MolMed SpA
  • Ono Pharmaceutical Co. Ltd
  • Nichi-Iko Pharmaceutical Co., Ltd
  • Others.

Market Segmentation:

Drug Type

  • Pemetrexed
  • Cisplatin
  • Carboplatin
  • Gemcitabine
  • Vinorelbine
  • Others

Route of Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Oncology Centers

Region

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Table of Contents

1. Executive Summary

  • 1.1. Global Malignant Mesothelioma Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 3.1. Global Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Pemetrexed
      • 3.1.1.2. Cisplatin
      • 3.1.1.3. Carboplatin
      • 3.1.1.4. Gemcitabine
      • 3.1.1.5. Vinorelbine
      • 3.1.1.6. Others
  • 3.2. Global Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Oral
      • 3.2.1.2. Parenteral
  • 3.3. Global Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospital Pharmacies
      • 3.3.1.2. Retail Pharmacies
      • 3.3.1.3. Oncology Centres
  • 3.4. Global Malignant Mesothelioma Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 4.1. North America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Pemetrexed
      • 4.1.1.2. Cisplatin
      • 4.1.1.3. Carboplatin
      • 4.1.1.4. Gemcitabine
      • 4.1.1.5. Vinorelbine
      • 4.1.1.6. Others
  • 4.2. North America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Oral
      • 4.2.1.2. Parenteral
  • 4.3. North America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospital Pharmacies
      • 4.3.1.2. Retail Pharmacies
      • 4.3.1.3. Oncology Centres
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.2. U.S. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.3. U.S. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 4.4.1.4. Canada Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 4.4.1.5. Canada Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 4.4.1.6. Canada Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 5.1. Europe Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Pemetrexed
      • 5.1.1.2. Cisplatin
      • 5.1.1.3. Carboplatin
      • 5.1.1.4. Gemcitabine
      • 5.1.1.5. Vinorelbine
      • 5.1.1.6. Others
  • 5.2. Europe Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Oral
      • 5.2.1.2. Parenteral
  • 5.3. Europe Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospital Pharmacies
      • 5.3.1.2. Retail Pharmacies
      • 5.3.1.3. Oncology Centres
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.2. Germany Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.3. Germany Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.4. U.K. Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.5. U.K. Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.6. U.K. Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.7. France Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.8. France Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.9. France Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.10. Italy Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.11. Italy Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 5.4.1.12. Italy Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 5.4.1.13. Turkey Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.14. Turkey Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.15. Turkey Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.16. Russia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.17. Russia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.18. Russia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Pemetrexed
      • 6.1.1.2. Cisplatin
      • 6.1.1.3. Carboplatin
      • 6.1.1.4. Gemcitabine
      • 6.1.1.5. Vinorelbine
      • 6.1.1.6. Others
  • 6.2. Asia Pacific Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Oral
      • 6.2.1.2. Parenteral
  • 6.3. Asia Pacific Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospital Pharmacies
      • 6.3.1.2. Retail Pharmacies
      • 6.3.1.3. Oncology Centres
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.2. China Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.3. China Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.4. Japan Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.5. Japan Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.6. Japan Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.7. South Korea Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.8. South Korea Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.9. South Korea Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.10. India Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.11. India Malignant Mesothelioma Market by Route of Administration,Value (US$Bn), 2018 - 2031
      • 6.4.1.12. India Malignant Mesothelioma Market by Distribution Channel, Value(US$Bn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 7.1. Latin America Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Pemetrexed
      • 7.1.1.2. Cisplatin
      • 7.1.1.3. Carboplatin
      • 7.1.1.4. Gemcitabine
      • 7.1.1.5. Vinorelbine
      • 7.1.1.6. Others
  • 7.2. Latin America Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Oral
      • 7.2.1.2. Parenteral
  • 7.3. Latin America Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospital Pharmacies
      • 7.3.1.2. Retail Pharmacies
      • 7.3.1.3. Oncology Centres
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.2. Brazil Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.3. Brazil Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.4. Mexico Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.5. Mexico Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.6. Mexico Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.7. Argentina Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.8. Argentina Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.9. Argentina Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Malignant Mesothelioma Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Malignant Mesothelioma Market Outlook, by Drug Type, Value (US$ Bn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Pemetrexed
      • 8.1.1.2. Cisplatin
      • 8.1.1.3. Carboplatin
      • 8.1.1.4. Gemcitabine
      • 8.1.1.5. Vinorelbine
      • 8.1.1.6. Others
  • 8.2. Middle East & Africa Malignant Mesothelioma Market Outlook, by Route of Administration, Value (US$ Bn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Oral
      • 8.2.1.2. Parenteral
  • 8.3. Middle East & Africa Malignant Mesothelioma Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospital Pharmacies
      • 8.3.1.2. Retail Pharmacies
      • 8.3.1.3. Oncology Centres
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Malignant Mesothelioma Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.2. GCC Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.3. GCC Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.4. South Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.5. South Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.6. South Africa Malignant Mesothelioma Market by Distribution Channel,Value (US$Bn), 2018 - 2031
      • 8.4.1.7. Egypt Malignant Mesothelioma Market by Drug Type, Value (US$Bn), 2018 - 2031
      • 8.4.1.8. Egypt Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.9. Egypt Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.10. Nigeria Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.11. Nigeria Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.12. Nigeria Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Malignant Mesothelioma Market by Drug Type, Value (US$ Bn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Malignant Mesothelioma Market by Route of Administration, Value (US$ Bn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Malignant Mesothelioma Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By Drug Type vs by Route of Administration Heat map
  • 9.2. Company Market Share Analysis, 2023
  • 9.3. Competitive Dashboard
  • 9.4. Company Profiles
    • 9.4.1. AstraZeneca Plc.
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Product Portfolio
      • 9.4.1.3. Financial Overview
      • 9.4.1.4. Business Strategies and Development
    • 9.4.2. Bristol-Myers Squibb Company
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Product Portfolio
      • 9.4.2.3. Financial Overview
      • 9.4.2.4. Business Strategies and Development
    • 9.4.3. F. Hoffmann-La Roche Ltd.
      • 9.4.3.1. Company Overview
      • 9.4.3.2. Product Portfolio
      • 9.4.3.3. Financial Overview
      • 9.4.3.4. Business Strategies and Development
    • 9.4.4. Merck & Co., Inc.
      • 9.4.4.1. Company Overview
      • 9.4.4.2. Product Portfolio
      • 9.4.4.3. Financial Overview
      • 9.4.4.4. Business Strategies and Development
    • 9.4.5. Novartis AG
      • 9.4.5.1. Company Overview
      • 9.4.5.2. Product Portfolio
      • 9.4.5.3. Financial Overview
      • 9.4.5.4. Business Strategies and Development
    • 9.4.6. Pfizer Inc.
      • 9.4.6.1. Company Overview
      • 9.4.6.2. Product Portfolio
      • 9.4.6.3. Financial Overview
      • 9.4.6.4. Business Strategies and Development
    • 9.4.7. Sanofi
      • 9.4.7.1. Company Overview
      • 9.4.7.2. Product Portfolio
      • 9.4.7.3. Financial Overview
      • 9.4.7.4. Business Strategies and Development
    • 9.4.8. Eli Lilly and Company
      • 9.4.8.1. Company Overview
      • 9.4.8.2. Product Portfolio
      • 9.4.8.3. Financial Overview
      • 9.4.8.4. Business Strategies and Development
    • 9.4.9. Teva Pharmaceuticals
      • 9.4.9.1. Company Overview
      • 9.4.9.2. Product Portfolio
      • 9.4.9.3. Financial Overview
      • 9.4.9.4. Business Strategies and Development
    • 9.4.10. Boehringer Ingelheim GmbH
      • 9.4.10.1. Company Overview
      • 9.4.10.2. Product Portfolio
      • 9.4.10.3. Financial Overview
      • 9.4.10.4. Business Strategies and Development
    • 9.4.11. Mylan N.V.
      • 9.4.11.1. Company Overview
      • 9.4.11.2. Product Portfolio
      • 9.4.11.3. Financial Overview
      • 9.4.11.4. Business Strategies and Development
    • 9.4.12. Fresenius Kabi AG
      • 9.4.12.1. Company Overview
      • 9.4.12.2. Product Portfolio
      • 9.4.12.3. Financial Overview
      • 9.4.12.4. Business Strategies and Development
    • 9.4.13. Sun Pharmaceuticals Industries Ltd
      • 9.4.13.1. Company Overview
      • 9.4.13.2. Product Portfolio
      • 9.4.13.3. Financial Overview
      • 9.4.13.4. Business Strategies and Development
    • 9.4.14. Corden Pharma International GmbH
      • 9.4.14.1. Company Overview
      • 9.4.14.2. Product Portfolio
      • 9.4.14.3. Financial Overview
      • 9.4.14.4. Business Strategies and Development
    • 9.4.15. Concordia International Corp
      • 9.4.15.1. Company Overview
      • 9.4.15.2. Product Portfolio
      • 9.4.15.3. Financial Overview
      • 9.4.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations

List of Region/Countries

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Turkey
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • South Korea
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제